Development and validation of a systematic UPLC-MS/MS method for simultaneous determination of three phenol impurities in ritonavir

Journal of Pharmaceutical and Biomedical Analysis

Volumn 90, Issue , 2014, Pages 127-133

  Venugopal, N ^a   Vijaya Bhaskar Reddy, A ^a   Madhavi, G ^a  

^a SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Antiretroviral drugs; Genotoxicity; Method validation; Ritonavir; Solution stability

Indexed keywords

4 NITROPHENOL; AMMONIA; AMMONIUM ACETATE; METHANOL; N PHENOXYCARBONYL LEVO VALINE; PHENOL; RITONAVIR; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CALIBRATION; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FLOW RATE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MASS SPECTROMETRY; NEGATIVE ION ELECTROSPRAY; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTIRETROVIRAL DRUGS; GENOTOXICITY; METHOD VALIDATION; RITONAVIR; SOLUTION STABILITY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; LIMIT OF DETECTION; NITROPHENOLS; PHENOLS; REPRODUCIBILITY OF RESULTS; RITONAVIR; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; VALINE;

EID: 84890877473     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.11.029     Document Type: Article

References (18)

1. Bolt H.M., Foth H., Hengstler J.G., Degen G.H. Carcinogenicity categorization of chemicals - new aspects to be considered in a European perspective. Toxicol. Lett. 2004, 151:29-41.
2. Jacobson Kram D., McGovern T. Toxicological overview of impurities in pharmaceutical products. Adv. Drug Deliv. Rev. 2007, 59:38-42.
3. EMA-CHMP Guideline on the Limit of Genotoxic Impurities CPMP/SWP/5199/02, EMA/CHMP/QMP/251344/2006 2006, 28 June, http://www.emea.europa.eu/.
4. US FDA Guidance for Industry: Genotoxic and Carcinogenic impurities in Drug Substances and Products: Recommended Approaches 2008, http://www.fda.gov/cder/guidance.
5. Indian Pharmacopoeia, Ghaziabad: Published by the Indian Pharmacopoeia Commission; 3 (2007) 1059-1060.
6. British Pharmacopoeia, London: Published by the Stationary Office, I and II (2009) 5227-5237.
7. Muller L., Mauthe R.J., Riley C.M., Andino M.M., De antonis D., Beels C., De george J., De knaep A.G.M., Ellison D., Fagerland J.A., et al. A rationale for determining, testing and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 2006, 44:198-211.
8. Ashby J., Tennant R.W. Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. Mutat. Res. 1988, 204:17-115.
9. Dias C.L., Rossi R.C., Donato E.M., Bergold A.M., Froehlich P.E. LC determination of ritonavir, a HIV protease inhibitor, in soft gelatin capsules. Chromatographia 2005, 62:589-593.
10. Yekkala R.S., Ashenafi D., Marien I., Xin H., Haghedooren E., Hoogmartens J., Adams E. Evaluation of an international pharmacopoeia method for the analysis of ritonavir by liquid chromatography. J. Pharm. Biomed. Anal. 2008, 48:1050-1054.
11. Donato E.M., Dias C.L., Rossi R.C., Valente R.S., Froehlich P.E., Bergold A.M. LC method for studies on the stability of lopinavir and ritonavir in soft gelatin capsules. Chromatographia 2006, 63:437-443.
12. Wang P.G., Wei J.S., Kim G., Chang M., El-Shourbagy T. Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction. J. Chromatogr. A 2006, 1130:302-307.
13. Rentsch K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B 2003, 788:339-350.
14. Carvalho A.Z., El-Attug M.N., Zayed S.E., Hove E.V., Duppen J.V., Hoogmartens J., Schepdael A.V. Micellar electrokinetic chromatography method for determination of impurities in ritonavir. J. Pharm. Biomed. Anal. 2010, 53:1210-1216.
15. Novakova L., Matysova L., Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006, 68:908-918.
16. Wren S., Tchelitcheff P. Use of ultra-performance liquid chromatography in pharmaceutical development. J. Chromatogr. A 2006, 1119:140-146.
17. ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology 2005.
18. Kakadiya P.R., Chandrasekhar T.G., Ganguly S., Singh D.K., Singh V. Low level determination of methyl methanesulfonate and ethyl methanesulfonate impurities in emtricitabine active pharmaceutical ingredient by LC-MS/MS using electrospray ionization. Anal. Chem. Insights 2011, 6:21-28.